CD4 and neoplasm: Interestingly, EBV-induced CD4+ T cells have the potential to exhibit cytotoxicity against EBV-negative tumors in vitro, suggesting a strategy to use EBV-specific CD4+ T cells for anti-tumor immunotherapy [15,16].